The extent and correlates of community-based pharmaceutical opioid utilisation in Australia

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 5, 2016, Pages 521-538

  Degenhardt, Louisa ^a   Gisev, Natasa ^a   Cama, Elena ^a   Nielsen, Suzanne ^a   Larance, Briony ^a   Bruno, Raimondo ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Analgesics; Drug utilisation; Opioids; Pharmacoepidemiology; Prescribing

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; HYDROMORPHONE; METHADONE; MORPHINE; NON PRESCRIPTION DRUG; OPIATE; OXYCODONE; TAPENTADOL; TRAMADOL; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

AGE DISTRIBUTION; ARTICLE; AUSTRALIA; DRUG UTILIZATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; LOWEST INCOME GROUP; PRESCRIPTION; PRIORITY JOURNAL; RURAL AREA; SEX RATIO; SOCIAL DETERMINANTS OF HEALTH; AGED; COMMERCIAL PHENOMENA; EMPLOYMENT; FEMALE; INCOME; MALE; MIDDLE AGED; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

AGE DISTRIBUTION; AGED; ANALGESICS, OPIOID; AUSTRALIA; COMMERCE; EMPLOYMENT; FEMALE; HUMANS; INCOME; LINEAR MODELS; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PRESCRIPTION DRUGS; SEX DISTRIBUTION;

EID: 84955257513     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3931     Document Type: Article

References (61)

1. Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009; 39(10): 676-81. doi:10.1111/j.1445-5994.2009.01982.x.
2. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011; 195(5): 280-4.
3. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379(9810): 55-70.
4. Fischer B, Nakamura N, Urbanoski K, Rush B, Rehm J. Correlations between population levels of prescription opioid use and prescription-opioid-related substance use treatment admissions in the USA and Canada since 2001. Public Health 2012; 126(9): 749-51. doi:10.1016/j.puhe.2012.04.010.
5. Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Pharmacoepidemiol Drug Saf 2013; 22(4): 438-42. doi:10.1002/pds.3404.
6. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop effectiveness and risks of long-term opioid therapy for chronic pain. Ann Intern Med 2015. doi:10.7326/m14-2559.
7. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006; 15(9): 618-27.
8. Rintoul AC, Dobbin MDH, Drummer OH, Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2011; 17(4): 254-9.
9. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011; 60(43): 1487-92.
10. Office of Applied Studies-Substance Abuse and Mental Health Services Administration. Emergency department trends from DAWN: final estimates 1995-2002. DAWN Series D-24, DHHS publication no. (SMA) 03-3780. Department of Health and Human Services: Rockville, MD, 2003.
11. Roxburgh A, Burns L, Drummer OH, Pilgrim J, Farrell M, Degenhardt L. Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug Alcohol Rev 2013; 32(3): 269-75. doi:10.1111/dar.12033.
12. Frei MY, Nielsen S, Dobbin MD, Tobin CL. Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. Med J Aust 2010; 193(5): 294-6.
13. Bond GR, Ho M, Woodward RW. Trends in hepatic injury associated with unintentional overdose of paracetamol (Acetaminophen) in products with and without opioid: an analysis using the National Poison Data System of the American Association of Poison Control Centers, 2000-7. Drug Saf 2012; 35(2): 149-57. doi:10.2165/11595890-000000000-00000.
14. Mort JR, Shiyanbola OO, Ndehi LN, Xu Y, Stacy JN. Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization. Drug Saf 2011; 34(11): 1079-88. doi:10.2165/11593100-000000000-00000.
15. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015; 156(4): 569-76. doi:10.1097/01.j.pain.0000460357.01998.f1.
16. Scholten W, Henningfield JE. A meta-analysis based on diffuse definitions and mixed quality literature is not a good fundament for decisions on treatment of chronic pain patients. Pain 2015; 156(8): 1576-7. doi:10.1097/j.pain.0000000000000213.
17. Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. Addiction 2013; 108(4): 688-98. doi:10.1111/j.1360-0443.2012.04005.x.
18. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; (1): CD006605. doi:10.1002/14651858.CD006605.pub2.
19. Day C, Conroy E, Lowe J, Page J, Dolan K. Patterns of drug use and associated harms among rural injecting drug users: comparisons with metropolitan injecting drug users. Aust J Rural Health 2006; 14(3): 120-5.
20. Keyes KM, Cerda M, Brady JE, Havens JR, Galea S. Understanding the rural-urban differences in nonmedical prescription opioid use and abuse in the United States. Am J Public Health 2014; 104(2): e52-9. doi:10.2105/ajph.2013.301709.
21. Nielsen S, Murnion B, Dunlop A, et al. Comparing treatment-seeking codeine users and strong opioid users: findings from a novel case series. Drug Alcohol Rev 2015; 34(3): 304-11. doi:10.1111/dar.12224.
22. Rintoul AC, Dobbin MDH, Drummer OH, Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2010. doi:10.1136/ip.2010.029611.
23. Hollingworth SA, Gray PD, Hall WD, Najman JM. Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiol Drug Saf 2015, 24: 628-636.
24. Hollingworth SA, Symons M, Khatun M, Loveday B, Ballantyne S, Hall WD, et al. Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. Aust N Z J Public Health 2013; 37(2): 132-8. doi:10.1111/1753-6405.12030.
25. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010; 106(2): 86-94. doi:10.1111/j.1742-7843.2009.00494.x.
26. Blanch B, Pearson S, Haber P. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol 2014; 78(5): 1159-66.
27. IMS Health. Australian Pharmaceutical Index: IMS Plus workshop manual Sydney: IMS Health Australia, 2009.
28. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63(1): 65-76.
29. Australian Bureau of Statistics. 1270055006C184 Postcode 2011 to Statistical Local Area 2011. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/1270.0.55.006July%202011?OpenDocument [5 December 2015].
30. Australian Bureau of Statistics. 1216.0.15.003 - Australian Standard Geographical Classification (ASGC) Remoteness Area Correspondences, 2006. http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1216.0.15.003Main+Features12006?OpenDocument [5 December 2015].
31. Australian Bureau of Statistics. 1216.0 - Australian Standard Geographical Classification (ASGC), July 2006, http://www.abs.gov.au/ausstats/abs@.nsf/mf/1216.0 [5 December 2015].
32. Australian Bureau of Statistics. 3235.0 Population by Age and Sex, Regions of Australia, 2012, http://www.abs.gov.au/Ausstats/abs@.nsf/mf/3235.0 [5 December 2015].
33. Maven Marketing. List of pharmacies and chemists in Australia. 2014; Available from: http://www.mavenmarketing.com.au/list-of-pharmacies-in-australia/ [14th March 2014]
34. Nielsen S, Degenhardt L, Hoban B, Gisev N. Comparing Opioids: A Guide to Estimating Oral Morphine Equivalents (OME) in Research. NDARC Technical Report No. 329. Sydney: National Drug and Alcohol Research Centre, UNSW Australia, 2014.
35. Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med 2011; 25(7): 725-32.
36. MIMs Australia. MIMs Online. Australia: MIMs. https://www.mimsonline.com.au/Search/Search.aspx [5 December 2015].
37. Environmental Systems Research Institute Inc. ESRI ArcGIS Desktop 10.2. Esri: California, 2013.
38. Derry S, Karlin SM, Moore RA. Single dose oral ibuprofen plus codeine for acute postoperative pain in adults. Cochrane Database Syst Rev 2015; 2 CD010107. doi:10.1002/14651858.CD010107.pub3.
39. Nielsen S, Tobin CL, Dobbin MD. OTC codeine: examining the evidence for and against. Aust Pharmacist 2012; 31(3): 236-40.
40. Roxburgh A, Hall WD, Burns L, et al. Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. Med J Aust 2015; 203(7): 299.
41. Toms L, Derry S, Moore RA, McQuay HJ. Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults. Cochrane Database Syst Rev 2009; (1) CD001547. doi:10.1002/14651858.CD001547.pub2.
42. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. New England J Med 2004; 351(27): 2827-31. doi:10.1056/NEJMoa041888.
43. Blyth FM, March LM, Brnabic AJM, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain 2001; 89(2-3): 127-34.
44. Nielsen S, Roxburgh A, Lintzeris N, Jefferson A, Degenhardt L. Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to 2011. Drug Alcohol Dependence 2015; 149: 212-9.
45. Prunuske JP, St Hill CA, Hager KD, et al. Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data. BMC Health Serv Res 2014; 14: 563. doi:10.1186/s12913-014-0563-8.
46. Havens JR, Oser CB, Leukefeld CG, et al. Differences in prevalence of prescription opiate misuse among rural and urban probationers. Am J Drug Alcohol Abuse 2007; 33(2): 309-17. doi:10.1080/00952990601175078.
47. Campbell G, Nielsen S, Larance B, et al. Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort. Pain Med 2015. doi:10.1111/pme.12773.
48. Clarke H, Soneji N, Ko DT, Yun L, Wijeysundera DN. Rates and risk factors for prolonged opioid use after major surgery: population based cohort study. BMJ (Clinical research ed) 2014; 348 g1251. doi:10.1136/bmj.g1251.
49. Cochran BN, Flentje A, Heck NC, et al. Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially-insured individuals. Drug Alcohol Depend 2014; 138: 202-8. doi:10.1016/j.drugalcdep.2014.02.701.
50. Rogers KD, Kemp A, McLachlan AJ, Blyth F. Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PLoS One 2013; 8(12): e80095.
51. Sullivan MD. Who gets high-dose opioid therapy for chronic non-cancer pain? Pain 2010; 151(3): 567-8.
52. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med (Malden, Mass) 2015. doi:10.1111/pme.12907.
53. Kaplovitch E, Gomes T, Camacho X, Dhalla IA, Mamdani MM, Juurlink DN. Sex differences in dose escalation and overdose death during chronic opioid therapy: a population-based cohort study. PLoS One 2015; 10(8e0134550). doi:10.1371/journal.pone.0134550.
54. Stafford J, Burns L. Australia drug trends 2014: findings from the Illicit Drug Reporting System (IDRS). In Australian Drug Trends Series No. 127. National Drug and Alcohol Research Centre, University of New South Wales: Sydney, 2015.
55. Mattick RP, Shand F, Cohen M, et al. A Review of Opioid Prescribing in Tasmania: A Blueprint for the Future. NDARC, University of New South Wales: Sydney, 2012.
56. Schmidt C. Experts worry about chilling effect of federal regulations on treating pain. J Natl Cancer Inst 2005; 97(8): 554-5. doi:10.1093/jnci/97.8.554.
57. Ringwalt C, Garrettson M, Alexandridis A. The effects of North Carolina's prescription drug monitoring program on the prescribing behaviors of the state's providers. J Prim Prev 2015; 36(2): 131-7. doi:10.1007/s10935-014-0381-0.
58. Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse: Res Treat 2009; 3: 41-51.
59. Degenhardt L, Gilmour S, Shand F, Bruno R, Campbell G, Mattick RP, et al. Estimating the proportion of prescription opioids that is consumed by people who inject drugs in Australia. Drug Alcohol Rev 2013; 32(5): 468-74.
60. Larance B, Lintzeris N, Bruno R, et al. The characteristics of a cohort who tamper with prescribed and diverted opioid medications. J Subst Abuse Treat 2015. doi:10.1016/j.jsat.2015.06.001.
61. Peacock A, Bruno R, Cama E, et al. Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. Drug Alcohol Rev 2015. doi:10.1111/dar.12279.